



# Senate

General Assembly

**File No. 94**

January Session, 2023

Senate Bill No. 80

*Senate, March 16, 2023*

The Committee on General Law reported through SEN. MARONEY of the 14th Dist., Chairperson of the Committee on the part of the Senate, that the bill ought to pass.

***AN ACT CONCERNING THE SHORTAGE OF CERTAIN DRUGS  
PRESCRIBED TO TREAT TYPE II DIABETES.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective from passage*) The Commissioner of  
2 Consumer Protection shall adopt regulations, in accordance with the  
3 provisions of chapter 54 of the general statutes, to ensure that there is a  
4 sufficient supply of dulaglutide and semaglutide to treat patients in this  
5 state who have been diagnosed with type II diabetes. Such regulations  
6 may, among other things, provide that no pharmacist shall dispense  
7 dulaglutide or semaglutide to treat any condition for which dulaglutide  
8 or semaglutide has not been approved by the federal Food and Drug  
9 Administration while such drug is in short supply in this state. For the  
10 purposes of this section, "dispense", "drug" and "pharmacist" have the  
11 same meanings as provided in section 20-571 of the general statutes.

This act shall take effect as follows and shall amend the following sections:

Section 1	<i>from passage</i>	New section
-----------	---------------------	-------------

**GL**      *Joint Favorable*

*The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.*

---

**OFA Fiscal Note****State Impact:** None**Municipal Impact:** None**Explanation**

The bill requires the Commissioner of Consumer Protection to adopt regulations regarding certain drugs that treat type II diabetes resulting in no fiscal impact to the state because the agency has the expertise to meet the requirements of the bill.

**The Out Years****State Impact:** None**Municipal Impact:** None

**OLR Bill Analysis****SB 80*****AN ACT CONCERNING THE SHORTAGE OF CERTAIN DRUGS  
PRESCRIBED TO TREAT TYPE II DIABETES.*****SUMMARY**

This bill requires the consumer protection commissioner to adopt regulations to ensure that there is a sufficient supply of dulaglutide and semaglutide to treat patients in the state with type II diabetes. The bill specifies that the regulations may, among other things, prohibit pharmacists from dispensing these medications off-label while the drug is in short supply in Connecticut (see BACKGROUND).

EFFECTIVE DATE: Upon passage

**BACKGROUND*****Dulaglutide and Semaglutide Supply Shortage***

Certain of these drugs, which are approved by the FDA for type II diabetes treatment, are currently included on the FDA's Drug Shortages list. Global demand for this class of drugs rose after clinical trials showed they provide weight loss benefits when prescribed off-label to non-diabetic patients.

**COMMITTEE ACTION**

General Law Committee

Joint Favorable

Yea 23    Nay 0    (03/02/2023)